Celyad Oncology S.A.
CYAD.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €29,497 | €10,032 | €11,433 | €54,848 |
| - Cash | €4,200 | €7,004 | €12,445 | €30,018 |
| + Debt | €17,536 | €1,058 | €255 | €2,632 |
| Enterprise Value | €42,833 | €4,086 | -€757 | €27,462 |
| Revenue | €186 | €102 | €0 | €0 |
| % Growth | 82.4% | – | – | – |
| Gross Profit | €919 | €33 | -€1,440 | -€1,520 |
| % Margin | 494.1% | 32.4% | – | – |
| EBITDA | -€5,391 | -€7,763 | -€39,695 | -€25,414 |
| % Margin | -2,898.4% | -7,610.8% | – | – |
| Net Income | -€5,824 | -€8,448 | -€40,935 | -€26,512 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| Operating Cash Flow | -€5,680 | -€15,202 | -€28,010 | -€26,643 |
| Capital Expenditures | -€118 | -€899 | -€123 | -€393 |
| Free Cash Flow | -€5,680 | -€16,101 | -€28,133 | -€27,036 |